Copenhagen, 19 October 2010 - NeuroSearch (NEUR) today announced that the
release date for the company's Q3 2010 interim report has been changed from 17
November to 18 November 2010.
Financial calendar for 2010
18 November 2010: Q3 2010 interim report
Patrik Dahlen
CEO
Contact persons:
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4460 8212 or +45 4017 5103
About NeuroSearch
NeuroSearch A/S is a leading CNS focused and European based biopharmaceutical
company listed on NASDAQ OMX Copenhagen A/S (NEUR). The company's core business
is development of novel drugs to treat diseases of the central nervous system,
and the pipeline comprises eight products in clinical development (Phase
I-III). These include Huntexil® (pridopidine), a unique orphan drug in Phase
III development for the treatment of Huntington's disease, and tesofensine
ready for Phase III development as a novel drug to treat obesity.
NeuroSearch is founded on a well-established drug discovery platform in the
field of ion channels and monoamine transporters, ensuring the continuous
production of novel preclinical development candidates. The company has
strategic drug discovery and development alliances with Janssen Pharmaceutica
and Eli Lilly as well as a licence collaboration with Abbott. Further,
NeuroSearch has equity interests in a number of private companies in the Life
Science industry.
